Gene expression levels of the glycolytic enzymes lactate dehydrogenase A 1 2 (LDHA) and phosphofructokinase platelet (PFKP) are good predictors of 3 survival time, recurrence and risk of death in cervical cancer. 4 Verónica Bolaños-Suárez¹, Ana Alfaro², Ana María Espinosa³, Ingrid Medina-5 Martínez⁴, Eligia Juárez⁵, Nicolás Villegas-Sepúlveda⁶, Marco Gudiño-Zavas¹, 6 América Gutiérrez-Castro⁵, Edgar Román-Bassaure⁷, María Eugenia Salinas-7 Nieves⁸, Sergio Bruno-Muñoz⁸, Oscar Flores-Herrera⁹, Jaime Berumen^{1*}. 8 9 1.Unidad de Investigación en Medicina Experimental, Facultad de Medicina, 10 Universidad Nacional Autónoma de México, Mexico City, Mexico 11 12 2. Anatomía Patológica. Hospital General de México, Dr. Eduardo Liceaga, 13 Mexico City, México. 3. Farmacología Clínica, Hospital General de México, Dr. Eduardo Liceaga, 14 Mexico City, México. 15 Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, 16 Universidad Nacional Autónoma de México, Mexico City, México. 17 5. Unidad de Medicina Genómica, Hospital General de México. Dr. Eduardo 18 19 Liceaga Mexico City, México. 6.Departamento de Biomedicina Molecular, Centro de Investigación y Estudios 20 Avanzados del Instituto Politécnico Nacional, Mexico City, México. 21 22 7. Servicio de Oncología, Hospital General de México, Dr. Eduardo Liceaga, 23 Mexico City, México. 8. Servicio de Ginecología, Clínica de Colposcopia, Hospital General de 24 México, Dr. Eduardo Liceaga, Mexico City, México. 25 9. Departamento de Bioquímica, Facultad de Medicina, Universidad Nacional 26 27 Autónoma de México, Mexico City, México. 28 29 *Corresponding author: Unidad de Investigación en Medicina Experimental, Facultad de Medicina, UNAM, Hospital General de México Dr. Eduardo Liceaga, 30 06720, Mexico City, Mexico, phone: +52 551850-4023. 31 32 e-mail: jaimeberumen47@gmail.com. 33 34 Keywords: Lactate dehydrogenase A (LDHA), phosphofructokinase platelet (PFKP), 35 36 cervical cancer, survival, risk of death.

37 Abstract 38 Background. Up to 74% of patients with cervical cancer (CC) may experience 39 40 recurrence after their treatment, and most of them are identified late when only the clinical parameters are used, which decreases their chances of recovery. Molecular 41 42 markers can improve the prediction of clinical outcome and identify therapeutic 43 targets in CC. Glycolysis is altered in 70% of CCs, so it could be a metabolic pathway 44 in which molecular markers associated with the aggressiveness of CC can be 45 identified.

Methods. The expression of 14 glycolytic genes was analyzed in 118 CC samples by microarrays, and only LDHA and PFKP were validated by qRT–PCR (n=58) and in second and third replicates by Western blotting (n=69) and immunohistochemistry (n=18).

Results. LDHA and PFKP were associated with poor overall survival [OS: LDHA HR=3.0 (95% CI= 1.1-8.2); $p=2.9 \times 10^{-2}$; PFKP HR=3.4 (95% CI= 1.1-10.5); $p=3.5 \times 10^{-2}$] and disease-free survival [DFS: LDHA HR=2.7 (95% CI= 1.6-6.3); $p=2.6 \times 10^{-2}$] independent of FIGO clinical stage. The risk of death was greater when both biomarkers were overexpressed than when using only FIGO stage [HR =7 (95% CI 1.6-31.1, $p=1.0 \times 10^{-2}$) versus HR=8.1 (95% CI=2.6-26.1; $p=4.3 \times 10^{-4}$)] and increased exponentially as the expression of LDHA and PFKP increased.

57 Conclusions. LDHA and PFKP at the mRNA and protein levels were associated with 58 poor overall survival, disease-free survival and increased risk of death of patients 59 with CC regardless of FIGO stage. The measurement of expression of these two 60 markers could be very useful to evaluate the clinical evolution and the risk of death 61 from CC and to make better therapeutic decisions at the beginning of treatment.

62

65 **1. Background**

66 Cervical cancer (CC) is the fourth most common cancer in women worldwide [1] 67 Persistent infection with human papillomavirus (HPV), particularly high-risk oncogenic 68 viruses, is the main etiological agent for the development of CC. Despite early 69 detection programs and vaccinations against the most oncogenic HPVs [2], it is 70 estimated that 569,000 new cases occur each year and cause 311,365 deaths 71 worldwide [1], indicating that CC continues to be a major health problem, mainly in 72 developing countries where most cases occur.

73 Treatment of CC includes surgery, radiotherapy and chemotherapy, which depend on 74 the clinical stage of the disease [3]. However, it is estimated that a significant percentage of patients have pelvic recurrence (10-23% in stage IB-IIB and 42-74% in 75 76 stage III-IVA) or metastases (16-26% in stage IB-IIB and 39-75% in stage III-IVA) 77 after treatment, and when this occurs, the patients often have poor survival [4], [5]. In 78 addition, only 32% of patients with recurrent disease are identified early (before 6 79 months) during medical follow-up, which decreases the chance of recovery and the 80 survival time [6]. Although the clinical International Federation of Gynecology and 81 Obstetrics (FIGO) stage, the clinical characteristics of the tumor, metastasis to lymph 82 nodes and parametrial invasion are predictors of recurrence and survival time, there 83 are no molecular markers approved for clinical use that predict the clinical evolution of patients with CC. Molecular markers alone or in conjunction with clinical data 84 85 improve the prediction of the clinical outcome and facilitate better therapeutic 86 decision-making, as has been demonstrated in colorectal [7] and breast [8] cancers.

Since glycolysis is increased in 70% of human cancers, with lactate production even in the presence of oxygen (Warburg effect) [9][10], it can be used to identify new

prognostic biomarkers in CC. In fact, the usefulness of several genes or proteins 89 90 involved in glycolysis has been investigated to evaluate survival and aggressiveness 91 in CC, such as glucose transporter 1 (GLUT1) [11], hexokinase 2 (HK2) [12], phosphofructokinase isoform M (PFKM) (as part of a genetic profile)[13] and total 92 93 lesion glycolysis (TLG), a parameter measurable through positron emission 94 tomography (PET) [14]. However, the predictive efficacy of these biomarkers either 95 has not been reported or has been reported to be intermediate. Perhaps PET is the 96 most efficient method; however, it is very expensive. On the other hand, it would be 97 desirable to identify molecular therapeutic targets in CC since the antitumor strategy 98 with specific target drugs is showing great benefit in many tumor types with a marked 99 decrease in side effects [15].

100 In a previous study, our group found a glycolytic gene profile in CC associated with a 101 decrease in survival [16]. In this paper, we investigate which genes of that glycolytic 102 expression profile are most highly associated with survival and tumor aggression in 103 CC. Of the genes finally identified, the mRNA and protein levels of lactate 104 dehydrogenase A (LDHA) and phosphofructokinase platelet (PFKP) were explored in a main discovery sample of 118 CCs, and they were validated in two additional 105 106 replicates (n = 58 and 69 CCs) and in 18 CC tissues preserved in paraffin. These two markers allow to evaluate of the clinical evolution and mortality of patients with CC 107 108 regardless of the FIGO stage.

109 **2. Materials**

110 Ethical consent

111 The study protocol was approved by the Scientific and Ethics Committee of the 112 General Hospital of Mexico (HGM) (approval number DIC/03/311/04/051). This study, 113 all experiments and analyses were performed in accordance with the Declaration of

Helsinki [17]. Written informed consent was obtained from all participants before their

inclusion in the study.

116 **Patient selection and clinical characteristics**

The study included 188 patients with CC (Supplementary Figure 1, Supplementary 117 118 Table 1), 10 patients with high-grade epithelial lesions (HG-CINs) and 36 women with 119 healthy cervical epithelium (HCE) evaluated in the Departments of Oncology and 120 Gynecology and Obstetrics of the HGM. Patients with CC were selected from a 121 previous study that included 462 patients recruited from November 2003 to April 122 2005 and from January 2006 to July 2007 [18]. The inclusion criteria were as follows: patients diagnosed with invasive CC, without previous treatments. Only patients from 123 124 whom high-quality RNA and tumor biopsies had more than 70% tumor cells were included in the present study. The exclusion criteria were insufficient quality of the 125 126 biological sample. All patients received complete clinical evaluation and were treated with surgery, radiation, chemotherapy, or a combination of these according to 127 128 American Cancer Society guidelines. Tumor staging was performed in accordance 129 with the latest International Federation of Gynecology and Obstetrics (FIGO) protocol 130 for gynecological cancer [19]. The average age of the patients was 51 years, with a 131 range of 23 to 89 years. After their treatment, they were followed up and evaluated 132 periodically at the HGM. HCE were obtained from patients who underwent 133 hysterectomy for myomatosis with a normal cervix for cytology and colposcopy as 134 described previously [18]. The tissues were frozen in liquid nitrogen and stored at -135 80°C.

136 **RNA isolation**

Total RNA from the samples was extracted with TRIzol[™] reagent (Invitrogen,
 Carlsbad CA, USA) according to the manufacturer's instructions. RNA integrity was

verified by agarose gel electrophoresis, determining the presence of 18S and 28Sribosomal RNA.

141

142 Glycolytic gene expression and data analysis

The glycolysis gene expression of 76 CC, 10 HG-CIN and 17 HCE tissues was examined using a Human Gene 1.0ST (HG-1.0ST) microarray and with the Human Gene Focus (HG-Focus) microarray in 42 CCs and 12 HCE (Affymetrix, Santa Clara, CA). Gene expression was obtained from two studies previously published by our working group in the Gene Expression Omnibus (GEO) database with accession numbers GSE52904 [16] and GSE39001 [18]. See supplementary text 1.

149 Quantitative PCR (qRT–PCR)

cDNA was synthesized using the High-Capacity cDNA Transcription Kit (Applied 150 Biosystems) using 5 µg of RNA according to the manufacturer's protocol. Gene 151 expression of LDHA, PFKP and an internal control (RPS13) was measured in 58 CC 152 and 19 HCE by qRT-PCR and TaqMan gene expression assays were used (LDHA, 153 Hs00855332_g1; PFKP, Hs00242993_m1; RPS13, HS 01011487_g1; Applied 154 155 Biosystem Inc.). The experiments were run in triplicate in a final volume of 20 µL, 156 including 200 ng of cDNA template using the TagMan® Universal PCR Master Mix (4304437, Applied Biosystems), according to the manufacturer's instructions. The 157 158 expression of the LDHA and PFKP genes was normalized in each tumor and control 159 sample with RPS13 using as previously reported [18]. The FC in expression was 160 calculated by dividing the median normalized intensity of each tumor sample by the 161 median normalized intensity of the whole control samples.

162 Western blot (WB)

LDHA and PFKP protein expression was determined using WB in 69 CC samples.
25 ng of protein was resolved on 8% SDS-PAGE and electrotransferred onto a

nitrocellulose membrane and incubated with a mouse monoclonal antibodies anti-165 human LDHA (H-10: sc-133123; 1:1,000) or PFKP (F-7: sc-514824; 1:200) and goat 166 β-actin antibody (I-19: sc-1616), (Santa Cruz Biotechnology, Inc.) overnight at 4°C. 167 The membranes were then incubated with horseradish peroxidase (HRP)-conjugated 168 secondary antibodies (anti-mouse IgG + IgM (H+L) antibodies; 1:10,00; Jackson 169 170 ImmunoResearch Laboratories, Inc.) and anti-goat IgG-HRP (sc-2354; 1:1,000; 171 Santa Cruz Biotechnology, Inc.) for 1 h at room temperature. Prestained Broad 172 Range SDS-PAGE Standards (BIO-RAD, CA) were used for molecular weight 173 estimation on gels. β-actin was used as an internal control. Loading buffer without 174 sample was used as negative control. The immunoreactive proteins were developed 175 using the SuperSignal[™] Chemiluminescent HRP Kit (Thermo Fisher Scientific). Densitometric analysis was performed with ImageJ (NIH, Bethesda, MD). The optical 176 density was calculated as OD=Log 10 (255/pixel value). 177

178 Immunohistochemistry (IH)

179 The protein expression of LDHA and PFKP was determined in 18 CC, 12 HCE and 6 180 metastatic samples by IH. Human paraffin-embedded tissue samples were collected 181 at the Pathology Department of HGM from patients evaluated from January 2008 to 182 March 2013. The inclusion criteria were women with CC at any FIGO stage whose 183 diagnostic biopsy was taken prior to treatment, with complete clinical data available, 184 and with follow-up data of at least 24 months after treatment. All patients received 185 complete clinical evaluation according to the ACS guidelines. Clinicopathological information was collected from medical records. Tissue microarrays (TMAs) were 186 187 built as previously described [18]. The TMA included kidney tumor tissue as a positive control, which was previously determined to present high LDHA and PFKP 188 expression (www. proteinatlas.org). IH was performed with the Ultra Streptavidin 189 190 (USA) HRP Detection Kit (Multi-Species) (BioLegend, CA) according to the

manufacturer's instructions. The following mouse monoclonal antibodies were used:
LDH (H-10) sc-133123 (1:200) and PFKP (F-7) sc-514824 (1:100) from Santa Cruz
Biotechnology (Santa Cruz, CA). Antigen-antibody complexes were detected using
the avidin-biotin peroxidase method, with 3,3'-diaminobenzidine-tetrahydrochloride as
a chromogenic substrate (DAB Chromogen Concentrate, BioLegend, CA), and the
sections were counterstained with hematoxylin. Assays were performed in triplicate.

197 **Quantitative image analysis**

Each tissue of the TMA was photographed in triplicate with a magnification of 400X using a Nikon Microphot FXA. The digital images were analyzed with ImageJ as previously described [20] and the intensity of DAB signal was transformed to optical density values: OD= -log (255* maximum level pixels)/average pixels. The integrated optical density (DOI) was calculated as OD x staining area.

203 Survival analysis

204 After the treatment was completed, each patient was clinically evaluated every 3 or 6 205 months by an experienced oncologist. Clinical data of the follow-up study were 206 obtained from the patient's medical record. Additionally, a social worker performed 207 phone calls and home visits to the patients every 6 months during the study. Survival 208 analysis was performed on all patients who received the full treatment. The mean 209 follow-up time was 60 months after the initial diagnosis. The patients designated as 210 censored referred to patients who were lost to follow-up or who died from causes 211 other than CC. Patients were considered lost when they did not attend medical 212 appointments for disease control, were not found at home visits or did not answer 213 phone calls. In this cohort, alive status was registered at the last follow-up, and death 214 was caused by a primary tumor of CC as a main cause and confirmed by the medical 215 record and the death certificate.

216 Statistical analysis

Data analysis was performed using SPSS software ver. 20. Receiver operating characteristic (ROC) curve analysis was performed, and the Youden index was used [21] to select the best cutoff points to distinguish tumors from nonsurviving and surviving patients or patients who survived with and without the disease using the expression values of glycolysis genes obtained by microarrays, qRT–PCR and WB. Expression values equal to or above the cutoff were considered upregulated, and those with values below the cutoff were considered downregulated.

The comparisons of the overall survival (OS) and disease-free survival (DFS) times between patients with upregulated and downregulated tumor genes were calculated by the Kaplan–Meier method and analyzed by the log-rank test. FIGO staging and glycolysis gene expression were included in univariate and multivariable Cox proportional hazards regression models. All tests were 2-sided, and *p* values less than 0.05 were considered statistically significant.

230 **3. Results**

231 Analysis of glycolytic gene expression in CC

232 The expression of genes involved in glycolysis included in the HG-1.0ST microarray 233 was analyzed in 103 cervical samples, including 76 CC, 10 HG-CINs and 17 HCE. As shown in Supplementary Figure 2, the 14 genes had significantly higher expression 234 235 levels in the invading CCs than in the controls. Interestingly, we were able to confirm 236 the difference between the invading cancers and the control group for 9 of these 237 genes (SLC2A1, HK2, PFKP, ALDOA, GAPDH, PGK1, ENO, PKM and LDHA) in a 238 second replicate with 42 invasive CCs and 12 controls, explored with a second 239 microarray (HG-Focus; see Supplementary Figure 3), which included only 9 of the 14 240 formerly explored genes. The samples were distributed into 3 groups, according to 241 the expression profile, in the hierarchical clustering analysis: upregulation (group 3); intermediate regulation (group 2), which could be divided into the intermediate 242 243 downregulation subgroup (group 2A) and the high intermediate upregulation

subgroup (group 2B); and downregulation (group 1). Group 3, in which most genes 244 were overexpressed in all samples, was composed only of CC (n=28) and the 3 CC-245 246 derived cell lines (HeLa, SiHa and CaSki). In contrast, in group 1, in which the glycolysis genes were not overexpressed, almost all controls were found (n=13, 247 248 76.5%), along with 4 of the 10 HG-CINs and a group of 15 CCs (19.7%). Group 2B, 249 like group 3, was composed only of CC, while group 2A, more like group 1, was 250 composed of HCE, HG-CINs and CCs (Figure 1, Supplementary Table 2). In the 251 hierarchical grouping with the samples explored with HG-Focus, the distribution of 252 the CCs and controls was very similar to the distribution obtained with the HG-1.0ST 253 data (Supplementary Figure 4, Supplementary Table 2). Interestingly, the frequency 254 of CCs with the highest clinical stage (\geq stage IIIA) predominated in group 3 (58.4%), 255 while those with lower clinical stages (\leq stage IIB) were distributed uniformly among the 4 groups ($p=5.0 \times 10^{-2}$, chi-square test) (Supplementary Table 2). 256

257 Effect of the gene expression of the 14 glycolysis genes on survival

258 Interestingly, the expression profile of the 14 genes explored significantly influences 259 the survival of patients with CC. Almost all women with CC (95%) whose tumors did 260 not overexpress glycolysis genes (groups 1 and 2A) survived more than 5 years. In 261 contrast, only 55% of patients with CC who had a glycolysis overexpression profile 262 (groups 2B and 3) survived more than 5 years (Supplementary Figure 5A), although the difference between the two groups presented marginal statistical significance (p=263 5.0 x10⁻², log-rank test). To investigate which genes, contribute most significantly to 264 265 that profile, survival was analyzed separately for each gene. Of the 14 genes 266 identified with the HG-1.0ST microarray, the overexpression of only 8 of them (GAPDH, PGK1, TPI1P1, LDHA, ALDO, PFKP, ENO, and GPI) significantly reduced 267 the % OS of the patients, with p values ranging from $p=1.0 \times 10^{-4}$ to $p=1.3 \times 10^{-2}$ in 268 the log-rank test (Supplementary Figure 5B, C, D, E, F, G, H, and I). In addition, 5 of 269

them (GPI, PFKP, TPI1P1, GAPDH, and LDHA) were also associated with a significant reduction in % DFS (Supplementary Figure 5J-O). Of the 9 genes explored with HG-Focus, the gene expression levels of only 3 of them (ALDO, PGK1 and LDHA) were also significantly associated with the reduction in % OS ($p = 3.3 \times 10^{-2}$, p $= 9.0 \times 10^{-3}$, and $p = 5.0 \times 10^{-2}$, respectively, log-rank test), and only 1 (LDHA; p = 3.0 $\times 10^{-2}$, log-rank test) was also associated with DFS (see Supplementary Figure 6).

276 To determine whether the overexpression of these genes is independent of clinical 277 stage, both variables were analyzed in a multivariate Cox proportional hazards 278 model. Due to the small number of patients (n=61), they were grouped into two 279 clinical groups, group 1 (\leq stage IIA, n=29) and group 2 (\geq stage IIB, n=32). Univariate analysis showed that the risk of death (hazard ratio, HR) of patients in 280 group 2 was 3.4 (95% confidence interval (CI) = 1.1-10.4; $p=3.6 \times 10^{-2}$. Cox test; 281 Table 1) times higher than that of patients in group 1. As expected, the 282 283 overexpression of 7 of the 8 genes conferred an increased risk of death, ranging from an HR of 2.8 (95% CI 1.0-7.6; $p = 3.7 \times 10^{-2}$) for the PGK1 gene to an HR of 9.2 284 $(95\% \text{ CI} = 1.2-69.5; p = 3.7 \times 10^{-2})$ for the ENO1 gene (see Table 1). 285

286 However, when explored in conjunction with FIGO stage in multivariate analysis, only the LDHA gene with an HR of 3.0 (95% CI =1.1-8.2; $p=2.9 \times 10^{-2}$), the PFKP gene 287 with an HR of 3.4 (95% CI = 1.1-10.5; $p = 3.5 \times 10^{-2}$) and the pseudogene TPI1P1 288 with an HR of 2.6 (95% CI = 1.0-7.9; $p = 4.0 \times 10^{-2}$) conferred an increased risk of 289 290 death, regardless of the FIGO clinical stage (Table 1). When DFS was analyzed, only LDHA with an HR of 2.7 (95% CI = 1.1-6.2; $p = 2.9 \times 10^{-2}$) was independent of FIGO 291 292 stage (Supplementary Table 3). LDHA experimental findings were also confirmed 293 with the HG-Focus data (see Supplementary Tables 4 and 5).

294 Validation of LDHA and PFKP expression at the mRNA and protein levels

The gene expression of the LDHA and PFKP genes was validated by gRT-PCR, 295 WB, and IH. gRT–PCR confirmed that the expression of both genes was higher in the 296 invading CCs (n=58) than in the HCE (n=19) However, the difference was much 297 greater for the LDHA (FC=100.3; p=9.8 x 10⁻⁸, Mann-Whitney test) than for PFKP 298 gene (FC=4.3, $p=2.0 \times 10^{-6}$, Mann–Whitney test, Figure 2A). Interestingly, we found 299 300 that the expression levels of LDHA and PFKP were in average 1.6 and 1.7 times 301 higher, respectively, in patients who died and/or presented active disease (recurrence) than in those who survived and were cured ($p=9.0 \times 10^{-3}$ to $p=2.8 \times 10^{-2}$; 302 Mann–Whitney test, see Supplementary Table 6). 303

In addition, we confirmed the presence of the LDHA and PFKP proteins by WB in 69 CC samples (15 of the 58 tumors explored for RNAs by qRT-PCR and 54 new CCs). LDHA and PFKP proteins were expressed at higher levels in the tumors of patients who did not survive (FC=14.9, $p=3.0 \times 10^{-3}$ and FC=21.4, $p=1.8 \times 10^{-3}$, respectively; Mann–Whitney test) or who survived with the disease (FC=29.1, $p=1.4 \times 10^{-4}$ and FC=17.2, $p=1.7 \times 10^{-3}$, respectively; Mann–Whitney test, Figure 2B-D) compared to tumors of patients who survived or disease-free survival more than 5 years.

Additionally, we analyzed the expression of these glycolytic enzymes by IH in HCE 311 312 tissues (n=12), CC tissues (n=18) and metastatic tissues (n=6) preserved in paraffin 313 from a new group of patients. LDHA and PFKP expression levels were significantly 314 higher in tumor tissues than in HCE tissues (FC=4.3 for LDHA and FC=27.2 for 315 PFKP); interestingly, the expression levels of both proteins were even higher in cervical metastases than in HCE (FC= 10.4 and 42.7, respectively) see 316 317 Supplementary Table 7). This suggests that overexpression of LDHA and PFKP 318 could be an important factor not only for tumor progression but also for the 319 development of metastases. Interestingly, we reconfirmed that LDHA expression was 320 higher in patients who had died and/or had active disease than in those who were

cured or survived more than 5 years (see Figure 3A-E and 3K). In contrast, there were not statistically significant differences in the PFKP expression between the groups (See Figure 3F-3J).

The LDHA and PFKP genes, at the mRNA or protein level, are good markers of survival in CC

At both the mRNA (n=58 CC) and protein (n=69) levels, we confirmed that the overexpression of LDHA and PFKP caused a significant decrease in OS and DFS during more than 5 years of follow-up; however, the results were stronger with the analysis of proteins. The analysis of mRNA is shown in Supplementary Table 8 and Figure 4A-C and 4G-I.

331 At the protein level, we found that the percentage of patients who survived decreased 332 markedly when LDHA or PFKP proteins were overexpressed compared to the group 333 in which these proteins were not overexpressed: 39% vs. 82% and 55% vs. 83% (both p < 0.05, log-rank test), respectively (see Figure 4D and 4E). Similar results 334 were found when DFS was analyzed (Figure 4J and 4K). Interestingly, when both 335 336 proteins were overexpressed (LDHA+/PFKP+), OS and DFS decreased dramatically 337 to 29% and 23%, respectively; in contrast, when there was a single overexpressed 338 protein, the survival rate was 64% in patients with and without the active disease, and 339 when neither of these two proteins was expressed, the survival rate was 90% (p=1.0x 10⁻³ and $p = 9.2 \times 10^{-5}$, log-rank test; see Figure 4F and 4L). 340

With the univariate Cox analysis, the risk of dying was much higher with advanced FIGO stages than with the overexpression of each of the two markers (Table 2). However, when both markers were overexpressed, they confer a greater risk of death than FIGO [HR =7 (95% CI 1.6-31.1, p=1.0 X 10⁻²) versus HR=8.1 (95% CI=2.6-26.1; p=4.3 x 10⁻⁴]. Similar figures were seen for DFS (Table 2). Interestingly, in the

multivariate analysis, both genes remained, together with clinical stage, in the models 346 347 of OS or DFS, indicating that they confer a risk of death independent of FIGO stage, 348 even of similar magnitude or greater than that conferred by FIGO stage when both markers are overexpressed [OS:HR= 6.1 (95% CI=1.3-31.2; $p=1.8 \times 10^{-2}$) vs. HR= 349 6.6 (95% CI=1.3-32.1; $p=2.5 \times 10^{-2}$) and [DFS:HR= 4.8 (95% CI=1.3-17.8; p=1.8 x 350 10^{-2}) vs. HR=5.1 (95% CI=1.5-16.6; p=7.0 x 10⁻³)]. In fact, the HR increased 351 352 exponentially as the level of expression of these markers increased, especially that of 353 LDHA (Figure 2E). In 5 patients, the HR was well above the average HR of 4, 354 reaching an HR value of 12.6 in the patient with an LDHA intensity of 83,538 OD 355 units.

356

357 4. Discussion

This is the first study in which it was identified that the overexpression of the LDHA and PFKP genes of the glycolysis pathway, both at the mRNA and protein levels, are good prognostic markers for OS and DFS in patients with CC, independent of FIGO stage. In fact, the risk of death when these two markers are elevated is equal to or greater than that of FIGO stage and increases exponentially with the protein level in the tumor, especially LDHA.

364 LDHA is part of the enzyme lactate dehydrogenase (LDH), which converts pyruvate 365 into lactate. This enzyme is composed of 4 subunits, which can be A (LDHA), B 366 (LDHB) or a combination of both [22]. Previous studies have shown that the isoforms 367 in which the A subunit predominates favor the conversion of pyruvate into lactate, 368 which stimulates glycolysis instead of oxidative phosphorylation. In contrast, when 369 the B subunit predominates, the reverse happens: lactate is converted to pyruvate 370 and metabolized by the Krebs/oxidative phosphorylation cycle [23]. In this work, we 371 show that in CC, subunit A is overexpressed, which indicates that LDHA favors the

production of lactate and, with it, anaerobic metabolism, which can provide growth 372 advantages to CC. On the other hand, PFKP, an isoform of the enzyme 373 374 phosphofructokinase 1 (PFK-1), stimulates the activity of glycolysis by catalyzing the 375 formation of fructose 1,6-bisphosphate from fructose 6-phosphate, the first rate-376 limiting step of glycolysis, and consequently the production of pyruvate. The 377 simultaneous overexpression of PFKP and LDHA makes sense for the tumor, 378 because the concerted action of the two enzymes in CC could rapidly metabolize 379 pyruvate to lactate, producing an acceleration of glycolysis (10-100 times faster than 380 total glucose oxidation in the mitochondria), achieving a large amount of anaerobic 381 ATP. This favors tumor growth and the development of more aggressive invasive 382 tumors.

383 No studies have assessed the influence of LDHA gene expression on the aggressiveness and survival of patients with CC. A couple of studies focused on 384 385 LDHA as a part of the tumor gene expression profile associated with metastases [24] 386 and resistance to chemotherapy [25], however, with contradictory results. In the 387 profile associated with resistance to chemotherapy, the LDHA gene was upregulated, 388 while in the profile associated with tumor metastases, the LDHA gene was 389 downregulated. Interestingly, in this last study, tumors FIGO stage ≤IIB 390 predominated, while in the first study, tumors FIGO stage ≥IIB predominated. This 391 could suggest that in tumors of greater clinical stage and larger size in which hypoxia 392 probably already exists, anaerobic metabolism predominates, while in early stages 393 with smaller tumor sizes, aerobic metabolism predominates.

On the other hand, several studies have shown that increased serum LDH activity in patients with CC was associated with poor prognosis and decreased OS [26] and DFS [27], with an increased risk of death or recurrence, independent of other clinical factors [28]. However, the limitation of these studies was that they did not

demonstrate whether the quantified LDH levels came specifically from CC or from
 other tissues, since this enzyme is produced in several tissues.

400 In several types of tumors (such as squamous cell carcinoma of the skin and melanoma), increased expression of glycolysis genes is associated with increased 401 402 tumor progression and decreased survival time in patients [29]. In addition, in many 403 types of cancers, it has been observed through PET using fluorodeoxyglucose (FDG) 404 that increased tumor glucose consumption is related to tumor aggressiveness [30]. 405 This phenomenon has also been demonstrated in animal models. For example, in 406 two mouse models of triple-negative breast cancer (TNBC), 4T1 and Py8119, 407 inhibition of glycolysis resulted in reduced tumor growth and metastases, which 408 prolonged mouse survival [31]. In CC cell lines, LDHA silencing has been shown to 409 decrease some neoplastic features in vitro. For example, HeLa and SiHa cells 410 decreased colony formation and invasion capacity when the gene is silenced by miR-411 34a. Interesting, when the activity of miRNA was finished, the activity of LDHA was 412 reactivated at baseline levels favoring cell proliferation and invasion, demonstrating 413 the importance of the expression of this gene for the tumor neoplastic phenotype 414 [32].

415 Considering the importance of the neoplastic phenotype and tumor metabolism, 416 LDHA could be a promising therapeutic target in CC. Several pharmacological 417 inhibitors for LDHA have previously been reported for use in cancer, and there are 418 currently several studies looking for more selective inhibitors [33] [34]. One of these 419 compounds, gossypol, is being used in clinical trials for the treatment of malignant 420 glioma (NCT00540722 and NCT00390403).

Although there are no PFKP reports in CC, this enzyme has been found to be overexpressed in HeLa cells [35] and related to the activation of tumor survival pathways via P44/42 mitogen-activated protein kinase (MAPK) [36]. Increased PFKP

expression and activity are related to neoplastic activity, metastasis production, and decreased survival in several types of cancer, primarily brain, kidney, and breast cancers [37], [38]. Other studies have shown that the inhibition of PFKP with specific siRNAs in lung cancer cell lines [37] and murine tumor models of leukemia [39] decreased the expression of the enzyme and glycolysis, glucose, lactic acid and ATP concentrations in the supernatant of cell cultures, as well as tumor growth and progression.

Simultaneous overexpression of PFKP and LDHA has previously been described in breast cancer cell lines (MDA-MB-231), in which PFKP regulation also regulates lactate production. Interestingly, quercetin treatment impaired PFKP-LDHA signaling axis thereby inhibiting aerobic glycolysis and migration and cell invasion *in vitro* by 80% [38], demonstrating that inhibition of both enzymes may be useful in the treatment of cancers in which these enzymes are activated, as in CC.

437 **5. Conclusions**

438 The overexpression of the glycolytic enzymes Lactate dehydrogenase A (LDHA) and 439 phosphofructokinase platelet (PFKP) was associated with poor overall and disease-440 free survival in CC. Overexpression of LDHA and PFKP genes increased the risk of 441 death from CC by 8 times, and this effect was independent of the FIGO clinical stage. 442 In fact, the risk of death from CC increased exponentially as the expression level of 443 these markers, mainly LDHA, increased. The measurement of gene expression of 444 these two markers could be very useful to evaluate the clinical evolution and the risk 445 of death from CC and to make better therapeutic decisions at the beginning of 446 treatment.

447 **6. Abbreviations**

ADPGK: ADP-dependent glucokinase; ALDOA: aldolase; AUC: area under the curve;
 CC: cervical cancer; DFS: disease-free survival; EDARADD: EDAR-associated death

domain; ENO1: enolase 1; FIGO: International Federation of Gynecology and 450 Obstetrics; FC: fold change; GPI: glucose-6-phosphate isomerase; GAPDH: 451 452 glyceraldehyde-3-phosphate dehydrogenase; HG-CIN: high-grade cervical intraepithelial neoplasia: HK2: hexokinase HR: 453 2; hazard ratio: IH: immunohistochemistry; LDHA: lactate dehydrogenase A; OS: overall survival: PFKP: 454 phosphofructokinase platelet; PGK1: phosphoglycerate kinase; PKM pyruvate kinase 455 456 M; qRT-PCR: quantitative real-time-polymerase chain reaction; SLC2A1: solute 457 carrier family 2 member 1; SLC9A1: solute carrier family 9 member A1; TP1P1: 458 triosephosphate isomerase 1 pseudogene 1; WB: Western blotting.

459 **Declarations**

460 **7. Ethics approval and consent to participate**

The study protocol was approved by the Scientific and Ethics Committee of the General Hospital of Mexico (HGM) (approval number DIC/03/311/04/051). This study, all experiments and analyses were performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants before their inclusion in the study.

466

- 467 8. Consent for publication
- 468 Not applicable.
- 469

470 **9.** Availability of data and materials

The datasets GSE52904 and GSE39001 analyzed during the current study are available in the GEO database (<u>https://www.ncbi.nlm.nih.gov/geo/</u>) and are available in the NCBI-GEO repository.

474 <u>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE52904</u>

475 <u>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE39001</u>

476

477

478 **10. Competing interests**

479 ICMJE uniform All authors have completed the disclosure form at 480 www.icmje.org/coi disclosure.pdf and declare: no support from any organization for 481 the submitted work; no financial relationships with any organizations that might have 482 an interest in the submitted work in the previous three years; no other relationships or 483 activities that could appear to have influenced the submitted work.

484

485 **11. Funding**

This research was conducted with support from the National Council on Science and
Technology (Conacyt) under grant numbers 8135/A1, 24341 (to JB) and Laboratorio
Huella Génica.

489 **12. Author contributions**

Study concept and design: J.B. and V.B.S. Performed the experiments: V.B.S., A.G.C., A.M.E., I.M.M., A.A., and E.J. Analyzed the data and wrote the manuscript: V.B.S and J.B. Contributed reagents/materials: O.F.H., N.V.S. Analyzed and interpreted the image data: M.G.Z. Clinically evaluated CC patients: E.R.B., M.E.S.N., S.B.M. Provided cervical specimens from these patients: E.R.B., S.B.M. All authors read and approved the manuscript. All authors gave final approval of the version to be published.

497

498 **13. Acknowledgments**

This study was performed as part of the requirements needed to obtain the Ph.D. degree of VB from Programa de Posgrado en Ciencias Biológicas, Universidad Nacional Autónoma de México (UNAM) and received a fellowship from CONACYT 502 (487890). We thank Dr. Valeria Barrón and Biologist Anabell Alvarado for training in
503 some laboratory techniques.

504 8. References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al.
 Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality
 Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians.
 2021; 71:209–49.

Zhu Y, Wang Y, Hirschhorn J, Welsh KJ, Zhao Z, Davis MR, et al. Human
 Papillomavirus and Its Testing Assays, Cervical Cancer Screening, and Vaccination.
 In: Advances in Clinical Chemistry. Academic Press Inc.; 2017. p. 135–92.

3. Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N.
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and
follow-up. Annals of Oncology. 2017;28:iv72–83.

4. Friedlander M, Grogan M. Guidelines for the Treatment of Recurrent and
Metastatic Cervical Cancer. The Oncologist. 2002;7:342–7.

517 5. Yoshida K, Kajiyama H, Utsumi F, Niimi K, Sakata J, Suzuki S, et al. A post-518 recurrence survival-predicting indicator for cervical cancer from the analysis of 165 519 patients who developed recurrence. Molecular and Clinical Oncology. 2017. 520 https://doi.org/10.3892/mco.2017.1530.

521 6. Duyn A, van Eijkeren M, Kenter G, Zwinderman K, Ansink A. Acta Obstetricia et
522 Gynecologica Scandinavica Recurrent cervical cancer: detection and prognosis. Acta
523 Obstet Gynecol Scand. 2002; 81:351–5.

Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM,
 Funkhouser WK, et al. Molecular biomarkers for the evaluation of colorectal cancer:
 Guideline from The American Society for Clinical Pathology, College of American
 Pathologists, Association for Molecular Pathology, and the American Society of
 Clinical Oncology. Journal of Clinical Oncology. 2017; 35:1453–96.

8. Van Poznak C, Somerfield MR, Bast RC, Cristofanilli M, Goetz MP, GonzalezAngulo AM, et al. Use of biomarkers to guide decisions on systemic therapy for
women with metastatic breast cancer: American Society of Clinical Oncology clinical
practice guideline. Journal of Clinical Oncology. 2015; 33:2695–704.

9. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nature
Reviews Cancer. 2004; 4:891–9.

10. Altenberg B, Greulich KO. Genes of glycolysis are ubiquitously overexpressed in
24 cancer classes. Genomics. 2004; 84:1014–20.

11. Huang X-Q, Chen X, Xie X-X, Zhou Q, Li K, Li S, et al. Co-expression of CD147
and GLUT-1 indicates radiation resistance and poor prognosis in cervical squamous
cell carcinoma. Int J Clin Exp Pathol. 2014; 7:1651–66.

12. Huang X, Liu M, Sun H, Wang F, Xie X, Chen X, et al. Original Article HK2 is a
radiation resistant and independent negative prognostic factor for patients with locally
advanced cervical squamous cell carcinoma. 2015.

13. Cai L, Hu C, Yu S, Liu L, Yu X, Chen J, et al. Identification and validation of a sixgene signature associated with glycolysis to predict the prognosis of patients with
cervical cancer. BMC Cancer. 2020;20.

14. Scher N, Castelli J, Depeursinge A, Bourhis J, Prior JO, Herrera FG, et al. (18F)FDG PET/CT parameters to predict survival and recurrence in patients with locally
advanced cervical cancer treated with chemoradiotherapy. Cancer/Radiotherapie.
2018; 22:229–35.

15. Ke X, Shen L. Molecular targeted therapy of cancer: The progress and future
 prospect. Frontiers in Laboratory Medicine. 2017; 1:69–75.

16. Medina-Martinez I, Barrón V, Roman-Bassaure E, Juárez-Torres E, GuardadoEstrada M, Espinosa AM, et al. Impact of gene dosage on gene expression,
biological processes and survival in cervical cancer: A genome-wide follow-up study.
PLoS ONE. 2014;9.

17. Riis P. Thirty years of bioethics: the Helsinki Declaration 1964-2003. New Rev
Bioeth. 2003;1:15–25.

18. Espinosa AM, Alfaro A, Roman-Basaure E, Guardado-Estrada M, Palma Í,
Serralde C, et al. Mitosis Is a Source of Potential Markers for Screening and Survival
and Therapeutic Targets in Cervical Cancer. PLoS ONE. 2013;8.

19. Bhatla N, Berek JS, Cuello Fredes M, Denny LA, Grenman S, Karunaratne K, et
al. Revised FIGO staging for carcinoma of the cervix uteri. International Journal of
Gynecology and Obstetrics. 2019; 145:129–35.

20. Ruifrok AC, Katz RL, Johnston A. Comparison of Quantification of Histochemical
Staining By Hue-Saturation-Intensity (HSI) Transformation and Color-Deconvolution.
2003.

21. Akobeng AK. Understanding diagnostic tests 3: Receiver operating characteristic
curves. Acta Paediatrica, International Journal of Paediatrics. 2007; 96:644–7.

569 22. Kopperschliger G, Kirchberger J. Methods for the separation of lactate 570 dehydrogenases and clinical significance of the enzyme. 1996.

23. Draoui N, Feron O. Lactate shuttles at a glance: From physiological paradigms to
anti-cancer treatments. DMM Disease Models and Mechanisms. 2011;4:727–32.

24. Huang L, Zheng M, Zhou QM, Zhang MY, Jia WH, Yun JP, et al. Identification of
a gene-expression signature for predicting lymph node metastasis in patients with
early stage cervical carcinoma. Cancer. 2011;117:3363–73.

25. An JS, Huang MN, Song YM, Li N, Wu LY, Zhan QM. A preliminary study of
genes related to concomitant chemoradiotherapy resistance in advanced uterine
cervical squamous cell carcinoma. Chinese Medical Journal. 2013;126:4109–15.

26. Wang H, Wang M sen, Zhou YH, Shi JP, Wang WJ. Prognostic values of LDH
and CRP in cervical cancer. OncoTargets and Therapy. 2020;13:1255–63.

27. Wang WJ, Li Y, Zhu J, Gao MJ, Shi JP, Huang YQ. Prognostic Values of
Systemic Inflammation Response (SIR) Parameters in Resectable Cervical Cancer.
Dose-Response. 2019;17.

28. Li J, Wu MF, Lu HW, Chen Q, Lin ZQ, Wang LJ. Pretreatment serum lactate
dehydrogenase is an independent prognostic factor for patients receiving
neoadjuvant chemotherapy for locally advanced cervical cancer. Cancer Medicine.
2016;5:1863–72.

588 29. Kunkel M, Reichert TE, Benz P, Lehr HA, Jeong JH, Wieand S, et al. 589 Overexpression of Glut-1 and increased glucose metabolism in tumors are 590 associated with a poor prognosis in patients with oral squamous cell carcinoma. 591 Cancer. 2003;97:1015–24.

30. Gambhir SS. Molecular imaging of cancer with positron emission tomography.
Nature Reviews Cancer. 2002;2:683–93.

31. Li W, Tanikawa T, Kryczek I, Xia H, Li G, Wu K, et al. Aerobic Glycolysis Controls
Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB
Isoform in Triple-Negative Breast Cancer. Cell Metabolism. 2018;28:87-103.e6.

32. Zhang R, Su J, Xue S-L, Yang H, Ju L-L, Ji Y, et al. HPV E6/p53 mediated downregulation of miR-34a inhibits Warburg effect through targeting LDHA in cervical
cancer. 2016.

33. Jafary F, Ganjalikhany MR, Moradi A, Hemati M, Jafari S. Novel Peptide
Inhibitors for Lactate Dehydrogenase A (LDHA): A Survey to Inhibit LDHA Activity via
Disruption of Protein-Protein Interaction. Scientific Reports. 2019;9.

34. Valvona CJ, Fillmore HL, Nunn PB, Pilkington GJ. The Regulation and Function
of Lactate Dehydrogenase A: Therapeutic Potential in Brain Tumor. Brain Pathology.
2016;26:3–17.

35. Moreno-Sánchez R, Marín-Hernández A, Gallardo-Pérez JC, Quezada H,
Encalada R, Rodríguez-Enríquez S, et al. Phosphofructokinase type 1 kinetics,
isoform expression, and gene polymorphisms in cancer cells. Journal of Cellular
Biochemistry. 2012;113:1692–703.

36. Cardim Pires TR, Albanese JM, Schwab M, Marette A, Carvalho RS, Sola-Penna
M, et al. Phosphofructokinase-P Modulates P44/42 MAPK Levels in HeLa Cells.
Journal of Cellular Biochemistry. 2017;118:1216–26.

37. Shen J, Jin Z, Lv H, Jin K, Jonas K, Zhu C, et al. PFKP is highly expressed in
lung cancer and regulates glucose metabolism. Cellular Oncology. 2020;43:617–29.

38. Umar SM, Kashyap A, Kahol S, Mathur SR, Gogia A, Deo SVS, et al. Prognostic
and therapeutic relevance of phosphofructokinase platelet-type (PFKP) in breast
cancer. Experimental Cell Research. 2020;396.

39. Qing Y, Dong L, Gao L, Li C, Li Y, Han L, et al. R-2-hydroxyglutarate attenuates
aerobic glycolysis in leukemia by targeting the FTO/m6A/PFKP/LDHB axis. Molecular
Cell. 2021;81:922-939.e9.

657 Figure legends

658

Figure 1. Unsupervised hierarchical cluster analysis of 14 glycolytic genes in 659 660 CC. The segregation of HCE (n=17), HG-CINs (n=10) and CC (n=76) is shown 661 according to the expression profile of 14 glycolytic genes. Four groups were 662 distinguished: the first group with downregulation of the genes (Group 1), the second 663 and third groups (Groups 2A and 2B) with intermediate expression levels, and the 664 fourth group with an upregulation profile (Group 3). Each column represents a sample, and each line represents a glycolytic gene. The number at the end of the CC 665 sample name (1 to 4) indicates the FIGO I, II, III, and IV stages of the patient. The 666 667 length and subdivision of the arms represent the relationship between the samples based on the intensity of gene expression: red for upregulation, blue for 668 669 downregulation, and white for no change in expression. The analysis was performed 670 with the expression values expressed in logarithmic form (base 2).

671 Figure 2. Validation of LDHA and PFKP expression in CC. The expression of LDHA and PFKP in CC was validated at the mRNA and protein levels by gRT-PCR 672 673 and WB, respectively. Panel A shows the qRT-PCR analysis of LDHA and PFKP 674 mRNA in 58 CCs. The expression was normalized with respect to the internal control (RPS13) and the control group by the double delta method using the final formula (2⁻ 675 ^{$\Delta\Delta CT$}). Panels B and C show representative images of WB of LDHA and PFKP 676 677 expression, respectively: surviving patients, nonsurviving patients, no recurrence 678 patients and recurrence patients. The molecular weight of the proteins is shown in 679 kilodaltons (kDa). The protein β -actin was used as an internal control. Panel D show 680 the mean expression <u>+</u> SD of LDHA and PFKP proteins between patients with CC 681 who survived (white bars, n=47) vs. those who died (gray bars, n=22). The intensity 682 of LDHA and PFKP was normalized with respect to β -actin. The expression is shown 683 as optical density (OD) units. The significant differences between the groups were

calculated with the Mann–Whitney U test, and p < 0.05 was considered statistically significant. Panel E shows the hazard ratio (HR) analysis in relation to LDHA and PFKP protein expression in CC. The risk of dying from CC increases exponentially as protein expression (OD) increases, but it is more evident with the expression of LDHA (dark blue circles represent nonsurviving patients, while light blue circles represent surviving patients) than PFKP (dark red circles represent nonsurviving patients, while light red circles represent surviving patients).SD= standard deviation.

691 Figure 3. Expression of LDHA and PFKP proteins by IH. The expression of the 692 LDHA and PFKP proteins was determined by immunohistochemistry (IH) and 693 compared between patients who survived without the disease (No recurrence) and 694 patients who died and/or remained with the disease (Recurrence). Histological 695 analysis included 12 controls, 18 CC and 6 metastatic tissues. Panels A-E show the 696 detection of the LDHA protein, and panels F-J show the detection of the PFKP 697 protein with a specific antibody. A representative image of the experiments is shown. 698 The specific signal for proteins is shown in brown color and counterstained with 699 hematoxylin in violet color. Original amplification 400x; the bars measure 20 µm. 700 Panels K show the quantitative analysis of LDHA and PFKP expression in CC tissues 701 of patients No recurrence vs recurrence determined by IH. The average optical 702 density and staining area of LDHA and PFKP (DOI) in the tissues were considered. 703 The mean ± SD of three independent experiments is shown. Mann–Whitney test was 704 performed to assess the difference between the groups, and p < 0.05 was considered statistically significant. SD= standard deviation. 705

Figure 4. Kaplan–Meier survival curves of LDHA and PFKP. OS analysis and according to the expression of LDHA and PFKP by qRT–PCR (panels A-C) and WB (panels D-F). DFS analysis according to the expression of LDHA and PFKP by qRT– PCR (panels G-I) and WB (panels J-L). The cutoff values were calculated using ROC curves. In the overall survival analysis, the red lines include the values of nonsurviving patients, while the blue line includes the values of surviving patients. In the disease-free survival analysis, the red lines contain the values of nonsurviving patients and surviving patients with the disease, while the blue lines include the values of surviving cured patients. Censored patients are shown marked with vertical bars. The p value was calculated with the log-rank test.

716 Supplementary Figure 1. Analysis workflow of 188 cervical cancer cases. Figure 717 shows the analysis workflow of the 188 CC cases explored in this study. The 718 expression of 14 genes involved in glycolysis were investigated in 76 CC with HG-719 1.0ST microarray and 9 genes were explored in 42 CC with HG-Focus, with 21 CCs 720 in common. Five-year survival was investigated in 61 of 76 patients with CC explored 721 with HG 1.0 ST and 36 of 42 patients investigated with HG-Focus. The expression of the LDHA and PFKP was validated by qRT-PCR, WB and IH. All patients explored 722 723 by qRT–PCR (n=58) and 59 of 69 patients studied by WB were included in the follow-724 up studies, with 15 CCs in common. The protein expression of LDHA and PFKP was 725 determined in 18 CC tissues by IH.

Supplementary Figure 2. Expression of glycolytic genes in CC. Box plots of the 726 expression of 14 genes of the glycolytic pathway obtained with the HG-1.0ST 727 728 microarray. The analysis was performed on 17 controls, 10 HG-CIN patients and 76 CC patients. The graphs show the value of the normalized fluorescence intensity (log 729 2) for each gene. The upper and lower limits of the boxes represent the 75th and 25th 730 percentiles, respectively. The mean is shown as the center black line inside the 731 732 boxes, and the median is shown as "+". The whiskers represent the maximum and 733 minimum values that lie within 1.5 times the interquartile range from the ends of the 734 frame. Values outside this range are displayed as black dots. The Mann-Whitney U

test was used to determine the significant differences between the groups, ***p*< 0.05,

736 *** *p*< 0.005.

Supplementary Figure 3. Box plots of the expression of 9 genes of the 737 glycolytic pathway obtained with the HG-Focus microarray. The analysis was 738 739 performed on 12 controls and 76 CC16+ patients. The graphs show the value of the 740 normalized fluorescence intensity (log 2) for each gene. The upper and lower limits of the boxes represent the 75th and 25th percentiles, respectively. The mean is shown 741 742 as the center black line inside the boxes, and the median is shown as "+". The 743 whiskers represent the maximum and minimum values that lie within 1.5 times the 744 interquartile range from the ends of the frame. Values outside this range are 745 displayed as black dots. The Mann-Whitney U test was used to determine the significant differences between the groups, *p < 0.05, **p < 0.005. 746

Supplementary Figure 4. Unsupervised hierarchical cluster analysis of 9 747 748 glycolytic genes in CC. The segregation of 12 controls and 42 CC HPV16+ is shown according to the expression profile of 9 glycolytic genes explored with the HG-749 750 Focus microarray, and 4 groups were distinguished: a first group with downregulation of the genes (Group 1), the second and third groups (Groups 2A and 2B) with 751 752 intermediate expression levels and the fourth group with an upregulation profile 753 (Group 3). Each column represents a sample, and each line represents a glycolytic 754 gene. The number at the end of the CC sample name (1 to 4) indicates the FIGO I, II, 755 III, and IV stages of the patient. The length and subdivision of the arms represent the 756 relationship between the samples based on the intensity of gene expression: red for upregulation, blue for downregulation, and white for no change in expression. The 757 analysis shows gene expression in log 2. 758

759

760 Supplementary Figure 5. Kaplan–Meier survival curves of HG-1.0 ST microarray. The OS (A–I panels) and DFS (J-O panels) of patients with CC were analyzed 761 762 according to the expression of the 14 glycolytic genes obtained with the HG-1.0ST microarray using the Kaplan-Meier method with the SPSS program. The cutoff 763 764 values of the expression of each gene that best separated the women were 765 calculated using ROC curves. In the overall survival analysis, the red lines include 766 the values of nonsurviving patients, while the blue line includes the values of 767 surviving patients. In the disease-free survival analysis, the red lines contain the 768 values of nonsurviving patients and surviving patients with the disease, while the blue 769 lines include the surviving cured patients. The mean follow-up time of patients 60 770 months after the initial diagnosis. Censored patients are shown marked with vertical bars. The *p* value was calculated with the log-rank test. 771

Supplementary Figure 6. Kaplan-Meier survival curves. The OS (A-J panels) and 772 773 DFS (K panel) of patients with CC were analyzed according to the expression of the 774 9 glycolytic genes obtained with the HG-Focus microarray using the Kaplan-Meier 775 method. The cutoff values of the expression of each gene that best separated the 776 patients were calculated using ROC curves. In the overall survival analysis, the red 777 lines include the values of nonsurviving patients, while the blue line includes the values of surviving patients. In the disease-free survival analysis, the red lines 778 779 contain the values of nonsurviving patients and surviving patients with the disease, 780 while the blue lines include the values of surviving cured patients. Censored patients 781 are shown marked with vertical bars. The *p* value was calculated with the log-rank 782 test.

- 785
- 786
- 787 788

Table 1. Univariate and multivariate analyses for the overall survival of patients with CC with Cox proportional hazards models including the expression of glycolytic genes explored with HG 1.0 ST microarray and FIGO clinical stage.

0	•	Univariate analysis ^e			Mu	Multivariate analysis ^f			
Covariates	n	HR⁵	95% CI	p°	HR⁵	95% CI	p°		
FIGO									
<u><</u> IIA	29	1			1.0				
<u>></u> IIB	32	3.4	1.1-10.4	3.6 x 10 ⁻²	3.3 ^d	1.1-9.6 ^d	3.5 x 10 ^{-2d}		
LDHA									
Low ^a	40	1.0			1.0				
High	21	3.1	1.1-8.3	2.7 x 10 ⁻²	3.0	1.1-8.19	2.9 x 10 ⁻²		
PFKP									
Low	32	1.0			1.0				
High	29	3.5	1.1-10.9	3.0 x 10 ⁻²	3.4	1.1-10.5	3.5 x 10 ⁻²		
TPI1P1									
Low	52	1.0		0	1.0				
High	9	3.7	1.3-10.9	1.5 x 10 ⁻³	2.6	0.8-7.87	4.0 x 10 ⁻²		
GAPDH									
Low	54	1.0		0	1.0		0		
High	7	5.6	1.9-16.3	2.0 x 10 ⁻³	4.0	1.3-12.3	5.2 x 10 ⁻²		
GPI									
Low	19	1.0		2	1.0		2		
High	42	8.5	1.1-64.1	3.9 x 10 ⁻²	7.9	1.0-60.0	5.6 x 10 ⁻²		
ENO									
Low	21	1.0		2	1.0		2		
High	40	9.2	1.2-69.5	3.2x 10 ⁻²	7.3	0.9-56.4	5.6 x 10 ⁻²		
PGK1									
Low	44	1.0		2	1.0		4		
High	17	2.8	1.0-7.6	3.7x 10 ⁻²	2.3	0.9-6.2	1.1 x 10 ⁻		
ALDOA									
Low	15	1.0		0	1.0				
High	46	5.8	0.7-44.3	8.7 x 10 ⁻²	4.9	0.6-37.6	1.2 x 10 ⁻¹		

792 Cl= confidence interval; HR= hazard ratio; FIGO stage=International Federation of Gynecology and Obstetrics
 793 stage.

794 a. Optimal cutoff values were selected according to the ROC analysis in relation to fold changes in genes 795 expression obtained with the Human Gene 1.0 ST microarray.

796 b. Adjusted hazard ratio.

797 c. Cox proportional hazards model.

798 d. These calculations were obtained in the multivariate analysis performed with LDHA. The values of FIGO obtained in the multivariate analysis with the other markers are not shown but are similar to these values.

800 e. Univariate analysis was performed considering one variable for the analysis.

801 f. Multivariate analysis was performed considering gene expression and FIGO stage for the analysis.

.

Table 2. Hazard ratio analyses of patients with CC with Cox proportional hazards 817 models including the expression of the glycolytic proteins LDHA and PFKP and FIGO

818 819

819 clinical stage										
		Univariate analysis ^e			Multivariate analysis ^f					
Covariates	n	HR℃	95% CI	pď	HR℃	95% CI	p ^d			
Overall Survival										
LDHA										
FIGO <u><</u> IIAª	27	1			1					
FIGO <u>></u> IIB	32	7.0	1.6-31.3	1.0 X 10 ⁻²	5.5	1.2-25.2	2.7 x 10 ⁻²			
Low ^b	43	1			1					
High	16	4	1.4-11.1	8.0 X 10 ⁻³	2.8	1.0-7.9	5.2 x 10 ⁻²			
PFKP										
FIGO <u><</u> IIA ^a	27	1			1					
FIGO <u>></u> IIB	32	7.0	1.6-31.3	1.0 X 10 ⁻²	6.9	1.5-30.5	1.1 x 10 ⁻²			
Low ^b	33	1			1					
High	26	3.3	1.1-10.55	4.0 X 10 ⁻²	3.2	1.0-10.2	4.6 x 10 ⁻²			
LDHA/PFKP ⁹										
FIGO <u><</u> IIAª	27	1			1					
FIGO <u>></u> IIB	32	7.0	1.6-31.3	1.0 X 10 ⁻²	6.1	1.3-31.2	1.8 x 10 ⁻²			
Low ^b	23	1			1					
One high	25	2.2	0.65-7.6	2.0 x 10 ⁻¹	5.3	1.0-25.6	4.0 x 10 ⁻²			
Two high	11	8.1	2.6-26.10	4.3 x 10 ⁻⁴	6.6	1.3-32.1	2.5 x 10 ⁻²			
Disease-free survival										
LDHA										
FIGO <u><</u> IIAª	27	1			1					
FIGO <u>></u> IIB	32	6.4	1.9-21.7	3.0 X 10 ⁻³	4.6	1.3-16.2	1.7 x 10 ⁻²			
Low ^b	43	1			1					
High	16	4.5	1.9-10.8	1.0 X 10 ⁻³	3.2	1.3-7.6	1.2 x 10 ⁻²			
PFKP										
FIGO <u><</u> IIAª	27	1			1					
FIGO <u>></u> IIB	32	6.4	1.9-21.7	3.0 X 10 ⁻³	6.1	1.7-20.6	4.0 x 10 ⁻²			
Low ^b	28	1			1					
High	31	3.2	1.2-8.2	1.8 X 10 ⁻²	2.9	1.1-7.5	2.8 x 10 ⁻²			
LDHA/PFKP ^g										
FIGO <u><</u> IIAª	27	1			1					
FIGO <u>></u> IIB	32	6.4	1.9-21.7	3.0 X 10 ⁻³	4.8	1.3-17.9	1.8 x 10 ⁻²			
Low ^b	23	1			1					
One high	25	2.2	0.7-7.6	2.0 x 10 ⁻¹	2.7	0.8-9.5	1.1 x 10 ⁻¹			
Two high	11	8.1	2.5-26.1	4.3 x 10 ⁻⁴	5.1	1.5-16.6	7.0 x 10 ⁻³			

820 a. FIGO stage analysis

821 b. Optimal cutoff values were selected according to the ROC analysis in relation to the expression of LDHA or

822 PFKP obtained with WB.

823 824 825 c. Adjusted hazard ratio.

d. Cox proportional hazards model.

e. Univariate analysis was performed considering one variable for the analysis.

f. Multivariate analysis was performed considering gene expression and FIGO stage for the analysis.

826 827 828 g. Low= downregulation of two genes; One high= upregulation of one gene; Two high= upregulation of LDHA and PFKP.

829 830 831 832 833 CI= confidence interval; HR = hazard ratio; FIGO stage= International Federation of Gynecology and Obstetrics stage

834

835

836

















Time (months)

80

n=26

n=32

 $p=1.4 \times 10^{-2}$

100 120

n=28

100 120

n=26

n=32

p=5.0 x 10⁻³

80 100 120

n=28

n=31

100 120

p= 1.3 x 10⁻²

0

Ò 20 40 60 80 p=9.2 x10⁻⁵

100 120

n=31

80